Table 1.
Baseline variables of those fulfilling the preliminary remission criteria and those not fulfilling the criteria at year 2*
| Total, N = 92 | Fulfilling criteria, n = 21 | Not fulfilling criteria, n = 71 | OR (95 CI) a | P value | |
|---|---|---|---|---|---|
| Age, median (IQR), y | 63 (55–71) | 66 (56–68) | 62 (54–72) | 1.00 (0.96–1.05) | 0.92 |
| Male, n (%) | 89 (97) | 20 (95) | 69 (97) | 0.58 (0.05–6.73) | 0.66 |
| Ethnicity, n (%) | |||||
| Māori | 8 (9) | 1 (5) | 7 (10) | 0.46 (0.05–3.94) | 0.48 |
| NZ European | 62 (67) | 15 (71) | 47 (66) | 1.28 (0.44–3.71) | 0.65 |
| Other | 8 (9) | 3 (14) | 5 (7) | 2.20 (0.48–10.09) | 0.31 |
| Pacific peoples | 14 (15) | 2 (10) | 12 (17) | 0.52 (0.11–2.52) | 0.42 |
| Age of first gout attack, median (IQR), y | 37 (30–52) | 38 (30–51) | 36 (29–55) | 1.00 (0.97–1.03) | 0.83 |
| Disease duration, median (IQR) | 20 (9–31) | 21 (11–26) | 20 (8–32) | 1.01 (0.98–1.04) | 0.65 |
| Body mass index median (IQR) | 31 (27–35) | 28 (27–31) | 31 (27–37) | 0.90 (0.82–1.00) | 0.051 |
| Baseline serum urate, median (IQR), mmol/L | 0.35 (0.31–0.40) | 0.36 (0.31–0.41) | 0.35 (0.31–0.40) | 0.10 (0.00–43.41) | 0.46 |
| Baseline subcutaneous tophus count, median (IQR) | 2 (0–4) | 1 (0–4) | 2 (0–5) | 0.95 (0.85–1.06) | 0.34 |
| Number of gout flares in preceding 3 mo at baseline, median (IQR) | 1 (0–2) | 0 (0–1) | 1 (0–2) | 0.72 (0.50–1.05) | 0.08 |
| Baseline pain, median (IQR), 10‐cm VAS | 0.35 (0.00–2.15) | 0 (0.00–0.60) | 0.50 (0.00–2.90) | 0.65 (0.43–0.99) | 0.04 |
| Baseline patient global assessment, median (IQR), 10‐cm VAS | 2.00 (1.00–3.50) | 1 (0.80–2.00) | 2.50 (1.00–3.50) | 0.82 (0.63–1.07) | 0.14 |
| Baseline serum creatinine, median (IQR), (μmol/L | 91 (82–105) | 90 (80–105) | 93 (84–105) | 1.00 (0.98–1.03) | 0.76 |
| Baseline creatinine clearance, median (IQR), mL/min | 72 (61–87) | 72 (61–82) | 73 (60–87) | 1.00 (0.97–1.02) | 0.69 |
| Comorbidities, n (%) | |||||
| Type 2 diabetes | 6 (7) | 1 (5) | 5 (7) | 0.66 (0.07–5.98) | 0.71 |
| High cholesterol | 40 (43) | 8 (39) | 32 (45) | 0.75 (0.28–2.03) | 0.57 |
| Hypertension | 45 (49) | 9 (43) | 36 (51) | 0.73 (0.27–1.95) | 0.53 |
| Cardiovascular disease | 11 (12) | 3 (14) | 8 (11) | 1.31 (0.32–5.47) | 0.71 |
| Kidney disease | 18 (20) | 3 (14) | 15 (21) | 0.62 (0.16–2.40) | 0.49 |
| Baseline DECT MSU crystal volume, median (IQR), cm3 | 0.12 (0.05–0.95) | 0.07 (0.03–0.10) | 0.18 (0.05–1.34) | 0.65 (0.47–0.90) | 0.01 |
| Baseline total radiographic damage score, median (IQR) | 5.70 (2.50–11.75) | 5.63 (3.13–11.38) | 5.88 (2.13–11.75) | 1.01 (0.96–1.06) | 0.75 |
| Baseline CT erosion score, median (IQR) | 7.00 (4.00–13.50) | 6.50 (4.00–11.50) | 7.00 (4.00–15.00) | 0.97 (0.90–1.05) | 0.46 |
| Randomization group, n (%) | |||||
| Intensive target group b | 46 (50) | 10 (48) | 36 (51) | 0.88 (0.33–2.34) | 0.80 |
*
CI, confidence interval; CT, computed tomography; DECT, dual‐energy computed tomography; IQR, interquartile range; MSU, monosodium urate; NZ, New Zealand; OR, odds ratio; VAS, visual analog scale.
a
Continuous measures were analyzed as the odds of a one‐unit difference.
b
Standard target group set as reference.